查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1422924

2024-2032年系统性红斑狼疮药物市场按药物类别（抗疟药、非类固醇抗发炎药、细胞毒性及免疫抑制药物、生物製剂等）、给药方式及地区

Systemic Lupus Erythematosus Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs, Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球系统性红斑狼疮（SLE）药物市场规模达到27亿美元。展望未来， IMARC Group预计到2032年市场规模将达到45亿美元，2024-2032年复合年增长率（CAGR）为5.83%患有系统性红斑狼疮的患者数量不断增加、公众宣传活动不断加强以及仿製药的容易获得是推动市场发展的一些关键因素。

系统性红斑狼疮 (SLE) 是一种自体免疫疾病，其特征是多变的临床表现、多系统发炎 (MIS) 和復发缓解病程 (RRMS)。它影响身体的许多部位，包括皮肤、关节、肾臟和大脑。它通常是由于各种遗传、环境和荷尔蒙因素引起的。其症状包括疲劳、关节疼痛和肿胀、头痛、皮疹、脱髮、贫血、凝血和发烧。系统性红斑狼疮由医疗保健提供者透过症状评估、身体检查、胸部 X 光检查、尿液分析和血液检查来诊断。可以使用治疗关节疼痛和僵硬的抗发炎药物、治疗皮疹的类固醇药膏、减少免疫反应的皮质类固醇以及治疗皮肤问题的抗疟药来缓解其症状。它还使用疾病缓解药物和标靶免疫系统药物来治疗更严重的病例。除此之外，还可以使用各种抑制免疫系统活性的免疫抑制药物来治疗。

系统性红斑狼疮 (SLE) 药物市场趋势：

自体免疫疾病在个体中的盛行率不断上升，以及患有系统性红斑狼疮的患者数量不断增加，是推动全球系统性红斑狼疮药物需求的主要因素之一。此外，越来越多的研究和诊断机构正在采取措施并进行公众宣传活动，以教育个人了解系统性红斑狼疮及其可能的治疗方法。此外，许多国家的政府和非政府组织（NGO）正在投资各种计画来开发新疗法并确定治疗 SLE 的相关药物标靶。再加上全球用于改善医疗基础设施和诊断技术的融资不断增加，正在推动市场成长。除此之外，透过线下和线上零售通路可以轻鬆获得各种用于缓解与系统性红斑狼疮相关的疼痛、发炎和僵硬的仿製药，这有利于市场的成长。它们通常涉及非处方药(OTC) 和处方非类固醇抗发炎药(NSAID)，例如阿斯匹灵、布洛芬(美林)、萘普生、塞来昔布(Celebrex)、双氯芬酸(扶他林)、二氟尼柳(Dolobid) 和吡罗昔康（费尔德内）。此外，羟氯奎药物使用的增加也促进了市场的成长。除此之外，个人和医疗保健专业人员对系统性红斑狼疮早期诊断和治疗益处的认识不断增强，正在影响系统性红斑狼疮药物的整体销售。

本报告回答的关键问题

  • 全球系统性红斑狼疮（SLE）药物市场有多大？
  • 2024-2032年全球系统性红斑狼疮（SLE）药物市场的预期成长率为何？
  • 推动全球系统性红斑狼疮（SLE）药物市场的关键因素是什么？
  • COVID-19 对全球系统性红斑狼疮 (SLE) 药物市场有何影响？
  • 根据药物类别，全球系统性红斑狼疮 (SLE) 药物市场的细分如何？
  • 根据给药方式，全球系统性红斑狼疮 (SLE) 药物市场的细分如何？
  • 全球系统性红斑狼疮（SLE）药物市场的主要区域有哪些？
  • 全球系统性红斑狼疮 (SLE) 药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球系统性红斑狼疮 (SLE) 药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 抗疟药
    • 市场走向
    • 关键环节
      • 氯奎
      • 羟氯奎
    • 市场预测
  • 非类固醇类抗发炎药（NSAIDS）
    • 市场走向
    • 市场预测
  • 细胞毒性和免疫抑制药物
    • 市场走向
    • 关键环节
      • 环磷酰胺
      • 甲胺蝶呤
      • 吗替麦考酚酯
      • 他克莫司
      • 环孢素
    • 市场预测
  • 生物製剂
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依交付方式

  • 静脉
    • 市场走向
    • 市场预测
  • 皮下
    • 市场走向
    • 市场预测
  • 口服
    • 市场走向
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：驱动因素、限制与机会

  • 概述
  • 司机
  • 限制
  • 机会

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AstraZeneca Plc
    • Aurinia Pharmaceuticals Inc.
    • GSK plc
    • ImmuPharma Plc
Product Code: SR112024A6799

Abstract

The global systemic lupus erythematosus (SLE) drugs market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.83% during 2024-2032.The increasing number of patients suffering from SLE, rising public awareness campaigns, and the easy availability of generic drugs represent some of the key factors driving the market.

Systemic lupus erythematosus (SLE) is an autoimmune medical condition characterized by protean clinical manifestations, multisystem inflammation (MIS), and a relapsing and remitting course (RRMS). It affects numerous parts of the body, including the skin, joints, kidneys, and brain. It is generally caused due to various genetic, environmental, and hormonal factors. Its symptoms include fatigue, joint pain and swelling, headache, rashes, hair loss, anemia, blood clotting, and fever. SLE is diagnosed by a healthcare provider using symptom assessments, physical examinations, chest X-rays, urinalysis, and blood tests. Its symptoms can be eased using anti-inflammatory drugs for joint pain and stiffness, steroid creams for rashes, corticosteroids to minimize the immune response, and antimalarial drugs for skin problems. It also uses disease-modifying drugs and targeted immune system agents for more severe cases. Besides this, it is treated using various immunosuppressive drugs that inhibit the activity of the immune system.

Systemic Lupus Erythematosus (SLE) Drugs Market Trends:

The increasing prevalence of autoimmune diseases among individuals and the rising number of patients suffering from SLE represents one of the major factors driving the demand for SLE drugs around the world. Moreover, the rising number of research and diagnostics institutes are undertaking measures and introducing public awareness campaigns to educate individuals about SLE and its possible treatments. In addition, governments and non-governmental organizations (NGOs) of numerous countries are investing in various programs to develop novel therapeutics and identify relevant drug targets for the treatment of SLE. This, coupled with the increasing financing to improve healthcare infrastructure and diagnostic technologies worldwide, is impelling the market growth. Apart from this, the easy availability of various generic drugs for relieving pain, inflammation, and stiffness associated with SLE through offline and online retail channels is favoring the market growth. They generally involve over the counter (OTC) and prescription-based nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen (Motrin), naproxen, celecoxib (Celebrex), diclofenac (Voltaren), diflunisal (Dolobid), and piroxicam (Feldene). Furthermore, the increasing use of Hydroxychloroquine drugs is contributing to the market growth. Besides this, the growing awareness among individuals and healthcare professionals about the benefits of early diagnosis and treatment of SLE is influencing the overall sales of SLE drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global systemic lupus erythematosus (SLE) drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on drug class and mode of delivery.

Drug Class Insights:

Antimalarials Drugs

Chloroquine

Hydroxychloroquine

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)

Cytotoxic and Immunosuppressive Drugs

Cyclophosphamide

Methotrexate

Mycophenolate Mofetil

Tacrolimus

Cyclosporine

Biologics

Others

The report has also provided a detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the drug class. This includes antimalarials drugs (chloroquine and hydroxycholroquine), non-steroidal anti-inflammatory drugs (NSAIDS), cytotoxic and immunosuppressive drugs (cyclophophamide, methotrexate, mycophenolate mofetil, tacrolimus, and cyclosporine), biologics, and others. According to the report, cytotoxic and immunosuppressive drugs represented the largest segment.

Mode of Delivery Insights:

Intravenous

Subcutaneous

Oral

A detailed breakup and analysis of the systemic lupus erythematosus (SLE) drugs market based on the mode of delivery has also been provided in the report. This includes intravenous, subcutaneous, and oral. According to the report, oral accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and the Middle East and Africa. According to the report, North America was the largest market for systemic lupus erythematosus (SLE) drugs. Some of the factors driving the North America systemic lupus erythematosus (SLE) drugs market included easy access to healthcare, the rising awareness about the benefits of early diagnosis and treatment of SLE, and the easy availability of various generic drugs.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global systemic lupus erythematosus (SLE) drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca Plc, Aurinia Pharmaceuticals Inc., GSK plc, and ImmuPharma Plc.

Key Questions Answered in This Report

  • 1. How big is the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 2. What is the expected growth rate of the global Systemic Lupus Erythematosus (SLE) drugs market during 2024-2032?
  • 3. What are the key factors driving the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 4. What has been the impact of COVID-19 on the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 5. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the drug class?
  • 6. What is the breakup of the global Systemic Lupus Erythematosus (SLE) drugs market based on the mode of delivery?
  • 7. What are the key regions in the global Systemic Lupus Erythematosus (SLE) drugs market?
  • 8. Who are the key players/companies in the global Systemic Lupus Erythematosus (SLE) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Systemic Lupus Erythematosus (SLE) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Antimalarials Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Chloroquine
      • 6.1.2.2 Hydroxychloroquine
    • 6.1.3 Market Forecast
  • 6.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cytotoxic and Immunosuppressive Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Cyclophosphamide
      • 6.3.2.2 Methotrexate
      • 6.3.2.3 Mycophenolate Mofetil
      • 6.3.2.4 Tacrolimus
      • 6.3.2.5 Cyclosporine
    • 6.3.3 Market Forecast
  • 6.4 Biologics
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Mode of Delivery

  • 7.1 Intravenous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Subcutaneous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

  • 9.1 Overview
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca Plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Aurinia Pharmaceuticals Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
    • 13.3.3 GSK plc
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 ImmuPharma Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Systemic Lupus Erythematosus Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Mode of Delivery (in %), 2023
  • Figure 6: Global: Systemic Lupus Erythematosus Drugs Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Systemic Lupus Erythematosus Drugs (Antimalarials Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Systemic Lupus Erythematosus Drugs (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Systemic Lupus Erythematosus Drugs (Cytotoxic and Immunosuppressive Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Systemic Lupus Erythematosus Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Systemic Lupus Erythematosus Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Systemic Lupus Erythematosus Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Systemic Lupus Erythematosus Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Systemic Lupus Erythematosus Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Systemic Lupus Erythematosus Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: North America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: North America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: United States: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: United States: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Canada: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Canada: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Asia-Pacific: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: China: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: China: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Japan: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Japan: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: India: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: India: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: South Korea: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: South Korea: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Australia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Australia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Indonesia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Indonesia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Europe: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Germany: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Germany: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: France: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: France: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United Kingdom: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United Kingdom: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Italy: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Italy: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Spain: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Spain: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Russia: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Russia: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Latin America: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Latin America: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Brazil: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Brazil: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Mexico: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Mexico: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market: Breakup by Country (in %), 2023
  • Figure 71: Middle East and Africa: Systemic Lupus Erythematosus Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Global: Systemic Lupus Erythematosus Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 73: Global: Systemic Lupus Erythematosus Drugs Industry: Value Chain Analysis
  • Figure 74: Global: Systemic Lupus Erythematosus Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Systemic Lupus Erythematosus Drugs Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Mode of Delivery (in Million US$), 2024-2032
  • Table 4: Global: Systemic Lupus Erythematosus Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Systemic Lupus Erythematosus Drugs Market: Competitive Structure
  • Table 6: Global: Systemic Lupus Erythematosus Drugs Market: Key Players